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Effect of 8-Bromo-Cyclic Guanosine Monophosphate (cGMP) on
Coronary Artery Constriction in Isolated Rabbit Hearts
RICHARD J. BING, MD, FACC, MAYTHEM SAEED, PHD
Pasadena, California
The vasodilator 8-bromo-guanosine 3': 5' -monophos-
phate (8-bromo-cGMP) effectively counteracts vaso-
pressin-induced coronary artery constriction in a sup-
ported perfusedworkingrabbit heart. In this preparation,
the coronary arteries remain in contact with the beating
heart. The obtuse marginal artery and portions of the
left anterior descending coronary artery were deprived
of endothelium. Perfusion was carried out with Krebs-
Henseleit solution, oxygenated with a disposable infant
oxygenator. The internal diameter of large coronary ar-
teries was determined by color arteriography (injection
of patent blue dye and gated photography). The effect
of vasopressin with and without the addition of8-bromo-
cGMP on cardiac performance (cardiac output, left ven-
tricular systolic pressure, left ventricular end-diastolic
pressure, maximal rate of rise in leftventricular pressure
[dP/dtmax] , mean aortic pressure) and large coronary
vessel and total coronary vascular resistance was deter-
mined in nine experiments. In addition, changes in coro-
nary sinus partial pressure of carbon dioxide(Peoz) and
pH were observed.
Vasopressinalone caused a significantdeclinein coro-
It is recognized that guanosine 3': 5' -monophosphate (cyclic
GMP) is released in arterial smooth muscle cells as a result
of the action of an endothelial-derived relaxing factor (1-3)
and of a series of vasodilator compounds (4-6), including
nitrovasodilators and acetylcholine (1-6). The presence of
vascular endothelium potentiates the release of cyclic GMP
and thus mediates the relaxing effect of acetylcholine both
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nary flow, myocardial oxygen consumption and coro-
nary sinus pH. Cardiac performance declined, probably
because of myocardial ischemia. Large coronary vessel
and total coronary vascular resistance rose. The vaso-
dilator 8-bromo-cGMP strongly inhibited the vasocon-
strictor action of vasopressin, counteracted the increase
in large and total coronary vascular resistance, pre-
vented the fall in myocardial oxygen consumption and
eliminated changes in pH or Pco, of coronary sinus
effluent, Because of the elimination of myocardial isch-
emia by 8-bromo-cGMP, cardiac performance was nor-
malized. The presence of 8-bromo-cGMP significantly
shifted the dose-response relation between vasopressin
and coronary flow and between vasopressin and total
coronary resistance to the right, and caused an increase
in the units for the concentration required to obtain 50%
of the maximal effect. The results indicate that 8-bromo-
cGMP has the potential to become a useful agent in
counteracting coronary artery constriction in vivo, par-
ticularly in those instances in which the coronary en-
dothelium has been damaged.
(J Am Coll CardioI1986;8:342-8)
in isolated coronary arteries (7-9) and in coronary arteries
perfusing an intact heart (10). An 8-bromo analogue of
cyclic GMP, 8-bromo-cGMP, first synthesized by Michal
et a1. (11), causes profound muscular relaxation in precon-
stricted isolated aortas (6,9,12). As compared with cyclic
GMP, 8-bromo-cGMP possesses greater cellular penetration
and is less vulnerable to the splitting action of a phospho-
diesterase (11). The extent of 8-bromo-cGMP-induced de-
creased tension depends on the initial tension of the nor-
adrenaline-stimulated tissue (6,13). Saeed and Bing (un-
published data, 1986) confirmed the relaxing effect of
8-bromo-cGMP on noradrenaline-preconstricted rabbit aor-
tic strips and the dependency of the degree of relaxation on
initial tension. They also found a higher degree of relaxation
in rabbit aortic strips that were deprived of endothelium.
This report is concerned with the effect of 8-bromo-
cGMP on endothelium-deprived coronary arteries perfusing
a beating heart. Constriction of the coronary arteries was
0735-1097/86/$3.50
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accomplished with the pituitary hormone vasopressin (8-
arginine vasopressin). The results demonstrate that in the
absence of endothelium, 8-bromo-cGMP diminishes or
abolishes vasopressin-induced large artery constriction, and
abolishes the increase in total coronary resistance and the
diminution in coronary flow. In the presence of 8-bromo-
cGMP , the dose-respon se relation between vasopressin and
total coronary flow and total coronary vascular resistance is
shifted to the right.
Methods
Experimental preparation. Nine male albino rabbits
weighing 2.1 to 2.8 kg were anesthetized with 30 mg/kg
body weight sodium pentobarbital , intravenously (Abbott
Laboratories) and heparinized with 400 Il.l/kg, intrave-
nously . Depth of anesthesia was ascertained by lack of cor-
neal reflexes. After tracheotomy, the rabbits were artificially
ventilated with 95% oxygen and 5% carbon dioxide using
a respirator (Mark 10, ventilator, Bird Corp.). Tracheotomy
and ventilation were carried out to supply the heart with
sufficient oxygen during thoracotomy. The heart was quickly
removed and placed in ice cold saline solution. The pre-
viously outlined technique was followed in principle (13, 14).
The obtuse marginal coronary artery and the first centimeter
of the anterior descending coronary artery were deprived of
endothelium by an abraded polyethylene tubing introduced
through the sinus of Valsalva . The aorta , pulmonary artery
and left atrium were cannulated . These procedures were
carried out with the heart submerged in chilled saline so-
lution.
The heart was then perfused in a Langendorff preparation
and the venae cavae and pulmonary veins were ligated.
Krebs-Henseleit solution at 37°C equilibrated for 20 minutes
with 95% oxygen and 5% carbon dioxide was used as per-
fusate (13,14) . The heart was then quickly transferred to a
modified supported working heart perfusion apparatus, again
using Krebs-Henseleit solution (500 ml) as perfusate. The
Krebs-Henseleit solution consisted of (in mM ): Na" 143,
K+ 5.94 , Ca2+ 2.54 , Mgz+ 1.19, phosphate 1.19, CI -
128, HCOi 25, sol- 1.2 and glucose 10; pH was main-
tained between 7.35 and 7.45 by adjusting the rate of bub-
bling of the gas mixture. Krebs-Henseleit solution was used
rather than a perfluorocarbon, because the detergent, plu-
ronic (F-68) and hydroxyethylstarch in the perfluorocarbon
might interfere with the effect of vasoactive substances.
Oxygenation of the perfusate was accomplished with a dis-
posable infant blood oxygenator (Spiroflo BOS-25 , Bentley
Laboratories Inc.). The final oxygen capacity of the per-
fusate at 760 mm Hg was 2.4 vol% (1.1 mM Oz). The
oxygen tension of perfusate entering the left atrium was
from 490 to 520 mm Hg. Gases in the perfusion fluid (partial
pressure of carbon dioxide [Pco-] and oxygen [Paz] and
pH) were determined for each control and before and after
injection of vasopressin with a radiometer (Radiometer,
ABL2 , Acid Base Laboratory , Copenhagen, Denmark).
Determination of myocardial oxygen consumption and
cardiac function. Myocardial oxygen consumption (MVOz
ml-min - I.g - I) was calculated using the formula:
MV0
2
= K x CF (Po2a - P0 2es),
Heart wet weight (g)
where P02a and POZes are the oxygen partial pressures in
millimeters of mercury in the arterial inflow and coronary
sinus outflow, respectively; K is the oxygen solubility con-
stant of the perfusion fluid (0.31 x 10- 4 ml 02/ml of KH
per mm Hg) and CF is the coronary flow (ml-min-I). Left
ventricular end-systolic and end-diastolic pressures, the
maximal rate of ventricular pressure change (dP/dtmax) ,
coronary flow and cardiac output were determined as de-
scribed previously (14). After simultaneous collection of
afferent left atrial inflow and coronary sinus flow (pulmo-
nary artery outflow), oxygen tension was measured .
Total coronary resistance (mm Hg-ml" I,min-I) was cal-
culated from mean aortic pressure (mm Hg) and coronary
flow (ml-min- I) . Measurement of large coronary vessel re-
sistance (obtuse marginal artery) was calculated using Poin-
seuille's equation (15):
8JL
Large vessel resistance (R) = 7T(r;t '
Because 'TT and JL are constants , the formula can be written:
using rj (internal radius) = d, (internal diameter)/2; there-
fore:
The heart rate was maintained at 180 beats/min by pacing
the right atrium with a Grass SD9 Stimulator (180 fre-
quency , 7 V, 0.2 ms duration, Grass Instrument Company) .
Mean aortic pressure was adjusted to between 54 and 58
mm Hg by increasing the outflow resistance. In a number
of experiments, the absence of endothelium was verified at
the end of the experiment by light microscopy after fixation
and staining with hematoxylin-eosin.
Application of vasopressin. The preparation was equi-
librated for 20 minutes. Four sets of experiments were car-
ried out. In the first, vasopressin (0.1 U) was injected four
times into the tube leading to the left atrium at intervals of
12 minutes . In the second set, the effect of vasopressin in
the presence of 8-bromo-cGMP (10- 4 Min 500 ml of per-
fustate) was studied; 8-bromo-cGMP (10 - 2 M) in 5 ml of
Krebs-Henseleit solution was added to the perfusate after
an equilibration period. Vasopressin was injected four times
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Figure 1. The effect of vasopressin on the internal diameter of
the obtuse marginal coronary artery expressed as percentile change.
Injections of vasopressin caused a marked diminution in large
coronary artery diameter. In the presence of 8-bromo-guanosine
3': 5' -rnonophosphate (8-Br-cGMP), the diameter of the artery
showed little change. The differences are highly significant.
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I mm Hg). Although significant differences were still pres-
ent between cardiac output and left ventricular end-systolic
pressure during the control period and after vasopressin
injection (cardiac ouput 9.8 ml-min-I, P < 0.05 and left
ventricular end-systolic pressure 4.2 mm Hg, p < 0.01),
these differences were less than before addition of 8-bromo-
cGMP (p < 0.001).
Changes in dissolved gases and pH in the perfusate after
injection of 0.1 U vasopressin were also studied. Pco, in
coronary sinus outflow increased significantly in all exper-
iments (ILl mm Hg, p < 0.01). Because Pco, in left atrial
inflow was constant (31.6 ± 0.2 mm Hg), coronary arterio-
venous carbon dioxide difference increased after vasopres-
sin, indicating myocardial ischemia. Ischemia was also re-
sponsible for the decline in pH in the coronary outflow (0.1,
P < 0.001). Myocardial oxygen consumption decreased
significantly (0.029 ml.g-l.min- 1, p < 0.001). After the
addition of 8-bromo-cGMP to the perfusate (10- 4 M), no
significant differences in Pco, and pH after vasopressin
injection were detected in coronary outflow. Myocardial
oxygen consumption also remained unchanged (before
8-bromo-cGMP: 0.061; after 8-bromo-cGMP: 0.058
ml-gt l-min -I).
Effect of vasopressin and 8-bromo-cGMP on large
coronary artery diameter and coronary vascular resis-
tance. The injection of vasopressin reduced the internal
diameter of the obtuse marginal coronary artery by 36%
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at intervals of 12 minutes. The perfusate containing vaso-
pressin as bypassed to avoid contamination of the perfusate.
The bypassed volume was replaced with an equal volume
of Krebs-Henseleit solution.
In the third set ofexperiments, the dose-response curves
were established between vasopressin and total coronary
flow and between vasopressin and total coronary vascular
resistance. The dose of vasopressin injected into the left
atrium ranged from 0.003 to 0.3 U. The interval between
injections depended on the attainment of a steady state. In
the fourth set of experiments, the dose-response curves were
determined in the presence of 10- 4 M 8-bromo-cGMP, which
was added to the perfusate at the onset of the experiment.
The dose of vasopressin injected into the left atrium (I ml
over a period of 15 seconds) varied from 0.03 to 1.0 U.
The internal diameter of the obtuse marginal coronary
artery was determined with color arteriography during the
first two injections of vasopressin (4,16). As described pre-
viously, this consisted of gated photography used to deter-
mine the internal arterial diameter after injection of 0.5 ml
of 0.1 % patent blue dye (Sigma Chemical Co.) into the left
atrium. The photographic slides were then projected onto a
screen with a magnification of 10 and the degree of con-
striction was quantitated. The resolution (the smallest dif-
ference in measurable change in internal diameter) is 0.08
mm (10,13).
Statistical analysis. The Student t test for paired and
unpaired data was used. Data were expressed as mean ±
SEM. Values for the concentration required to obtain 50%
of the maximal effect (EDso) in dose-response curves were
determined according to the method of Patil et al. (17) and
Fleming et al. (18).
Drugs. The following pharmacologic agents were used:
8-bromo-cyclic guanosine 3': 5' -monophosphate (8-bromo-
cGMP) (Sigma Chemical Co.) and 8-arginine vasopressin
(Parke-Davis).
Results
Effect of vasopressin and 8-bromo-cGMP on cardiac
performance, pH and myocardial oxygen consumption.
The effect of four repeated intraatrial injections of vaso-
pressin (0.1 U) was studied in nine preparations. A signif-
icant decline in dP/dt (230 mm Hg-s-1, P < 0.05), left
ventricular end-systolic pressure (9.5 mm Hg, p < 0.01),
mean aortic pressure (3.4 mm Hg, p < 0.05) and cardiac
output (41 ml.min- 1, p < 0.001) was observed. Left ven-
tricular end-diastolic pressure rose significantly (6.15 mm
Hg, p < 0.01). Addition of 8-bromo-cGMP eliminated the
response to vasopressin. In most instances, the difference
between values in the control period and after vasopressin
was not significant (dP/dt 118 mm Hg-s- I, left ventricular
end-diastolic pressure 0.8 mm Hg; mean aortic pressure
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Figure 2. Vasopressin resulted in a marked percentile increase in
large coronary vessel resistance. Large coronary vascular resis-
tance remained unaffected in the presence of 8-bromo-guanosine
3' :5'-monophosphate (S-Br-cGMP). The differences are highly
significant.
2000
after the first injection and by 40% after the second injection
(p < 0.01, Fig. I). After addition of 8-bromo-cGMP, va-
sopressin failed to constrict the artery (2% after the first and
4.5 % after the second injection) (Fig. I ). The difference in
response between vasopressin alone and after addition of 8-
bromo-cGMP was highly significant (p < 0.01 after both
injections). As the internal diameter declined, calculated
large coronary vascular resistance rose by 1,150% (Fig. 2);
8-bromo-cGMP prevented the increase in large coronary
vascular resistance. The differences in response to vaso-
pressin in the absence and presence of 8-bromo-cGMPwere
highly significant (p < 0.01). As a result of vasoconstric-
tion, vasopressin markedly decreased coronary flow (51%)
and increased total coronary vascular resistance (120%) (Fig.
3 and 4). Tachyphylaxis to vasopressin was absent, because
the response of the coronary flow and resistance remained
constant for the period of observation (40 minutes). The
presence of 8-bromo-cGMP greatly diminished the fall in
coronary flow and the rise in total coronary vascular re-
sistance.
Dose-response curves with vasopressin with and with-
out 8-bromo-cGMP. The dose-response relation between
the amount of vasopressin injected and coronary flow is
shown in Figure 5; 8-bromo-cGMP significantly inhibited
the vasoconstrictor activity of vasopressin in a dose-depen-
dent fashion. There was no evidence of tachyphylaxis. EDso
was 0.05 U of vasopressin without and 0.12 U of vaso-
pressin with 8-bromo-cGMP. The dose-response relation
between intraatrial vasopressin and total coronary vascular
resistance was similar (Fig. 6), with highly significant in-
hibition of vasoconstriction. EDsowas 0.15 U of vasopressin
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Flgure 4. Effect of vasopressin on percentile changes in total
coronary vascular resistance in the presence and absence of 8-
bromo-guanosine 3' :5'-monophosphate (8-Br-cGMP). A marked
increaseof total coronary vascularresistance occurred after injec-
tionof vasopressin. In the presence of 8-bromo-guanosine 3' :5'-
monophosphate, the increase in total coronary vascular resistance
was negligible. The differences are highly significant.
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Figure 3. Percentile effect of vasopressin on coronary flow with
and without8-bromo-guanosine 3' :5'-monophosphate(8-Br-cGMP).
Vasopressin markedly decreased coronary flow. In the presence
of 8-bromo-guanosine 3': 5'-monophosphate vasopressin had little
effect. The differences are highly significant.
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Discussion
Properties of 8-bromo-cGMP and its relation to en-
dothelium. The effect of several vasodilators, such as ni-
troprusside and nitroglycerin, on vascular smooth muscle is
Figure 5. Dose-response relation between vasopressin and total
coronary flow. The curve was shifted to theright with theaddition
of 8-bromo-guanosine 3': 5'-monophosphate (8-Br-cGMP), indi-
cating marked inhibition of vasopressin activity in a dose-depen-
dent fashion and in a noncompetitive manner. EDso was 0.05 U
without and0.12 U in the presence of 8-bromo-guanosine 3' :5'-
monophosphate,
without and 0.2 U of vasopressin in the presence of
8-bromo-cGMP. The latter inhibited the effect of vaso-
pressin in a noncompetitive manner.
The effect of 8-bromo-cGMP also altered the dose-re-
sponse curve of left ventricular end-systolic pressure. car-
diac ouput, myocardial oxygen consumption, PC02 and pH
to rising doses of vasopressin. As a consequence, the EDso
was shifted to the right after doses of vasopressin of from
0.03 to I U in the presence of 8-bromo-cGMP (10- 4 M );
EDso changed from O. 10 to O.17 U for left ventricular end-
systolic pressure, from 0.07 to 0.14 U for cardiac output
and from 0.06 to 0.14 U for myocardial oxygen consump-
tion. The presence of 8-bromo-cGMP also diminished the
arteriovenous carbon dioxide difference at high concentra-
tions of vasopressin (for example, at 0.3 U of vasopressin,
the coronary arteriovenous Pco, difference was 50%; 8-
bromo-cGMP reduced this difference to 21%). The differ-
ence in pH at 0.3 U of vasopressin between coronary arterial
and venous outflow was 4%; 8-bromo-cGMP reduced it to
1.5%.
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mediated through activation of guanylate cylase (cGMP)
(2,6,19). Rapoport and Murad (20) demonstrated that the
relaxing effect initiated by endothelium that is responsible
for vasodilation (the endothelial-derived relaxing factor of
Furchgott and Jothianadan [3]) is also mediated through the
formation of cGMP.
An 8-substituted guanosine derivative, 8-bromo-cGMP,
has considerably greater vasodilator properties than its un-
substituted parent substance. It was synthesized by Michal
et al. (II ) in 1970, who examined the effect of various
phosphodiesterases on the splitting action of cyclophos-
phates. They found that the rate of degradation is less when
substitution takes place in the 8 position of the purine ring.
The cell wall is more readily penetrated by 8-bromo-cGMP
than by cGMP, and the former is an effective relaxant of
tracheal smooth muscle (II). Like nitroglycerin, 8-bromo-
cGMP is also an effective antagonist of vasconstriction in-
itiated by alpha, receptors (21), which are the dominant
receptors in the coronary arteries (22); 8-bromo-cGMP was
a more active relaxant. The extent of relaxation depends on
the initial tension induced by noradrenaline as the precon-
stricting agent, as shown by Schultz et al. (23). These find-
ings were confirmed by Saeed and Bing (unpublished data,
Figure 6. The dose-response relation between vasopressin and
total coronary vascular resistance in the absence and presence of
8-bromo-guanosine 3': 5'-monophosphate (8-Br-cGMP) . Signifi-
cant inhibition of coronary vasoconstriction is indicated by a shift
of the curve to the right. EDso was 0.15 U without and 0.2 U in
the presence of 8-bromo-guanosine 3' :5'-monophosphate.
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1986), who, in addition, discovered that in rabbit aortic
rings the relaxing effect was potentiated in arteries deprived
of endothelium . Removal of endothelium potentiates the
response to other vasocon strictors as well. For example,
Carrier and White (24) found that removal of the vascular
endothelium increases the maximal response to selective
alpha, agoni sts, and Godfraind (25) noted that selective
removal of endothelial cells shifted concentration-effect curves
of noradrenaline to the left. Like nitroprusside or cGMP ,
the action of 8-bromo-cGMP is mediated through incor-
poration of phosphorus-32 into various soluble or particulate
proteins in an aortic preparation (4,5).
. Antagonistic effects of 8-bromo-cGMP on vasopres-
sin. Our results confirm that 8-bromo-cGMP is effective in
dilating constricted coronary arteries that are deprived of
endothelium and constricted with vasopressin in perfused
supported heart preparations. In this series, vasopressin is
used to constrict the vessels; Heyndrickx et al. (26) showed
that in doses of 1.2 jLmollkg, vasopres sin causes marked
coronary constriction (140%). After removal of endothe-
lium, vasopressin induces further constriction in coronary
artery strips (27). Our findings demonstrate that vasopres sin
significantly diminishes large coronary artery diameter (Fig.
1) and increases large coronary artery vascular resistance in
the absence of endothelium (Fig. 2). Several workers (27-29)
found that in coronary arteries with intact endothelium, va-
sopressin causes relaxation. In agreement with a series of
researchers (26 ,30-33), we found that the compound also
increases total coronary vascular resistance and dimini shes
coronary flow (Fig. 4 and 5) . Coronary flow is also reduced
by vasopre ssin in the study of Wilson et al. (34). Vaso-
pressin cause s marked depre ssion of myocardial perform-
ance: dP/dt, left ventricular systolic pressure, mean aortic
pressure and cardiac output diminish significantly, whereas
left ventricular end-diastolic pressure increases. The sig-
nificant decline in myocardial oxygen consumption, the in-
crease in arteriovenous oxygen difference and in Pco, of
coronary sinus outflow , together with the fall in coronary
sinus pH , are indications of myocardial ischemia due to
vasospasm. A decrease in myocardial contra ctility has also
been described by Green et al. (35) , occurring as a result
of myocardial ischemia after sufficiently large doses of va-
sopressin (3,4,36).
The presence of 8-bromo-cGMP strongly inhibits the
vasoconstrictor action of vasopressin; it counteracts the de-
crease in internal diameter of large coronary vessels as well
as the increase in large vessel and total coronary flow (Fig .
4). As a result , myocardial ischemia is absent. In the pres-
ence of 8-bromo-cGMP, vasopressin cause s no significant
changes in pH or Pco, of coronary sinus effluent and pre-
vents the fall in myocardial oxygen consumption and myo-
cardial contractility. It antagonizes the effects of vasopressin
on left ventricular end-diastolic pressure and mean aortic
pressure. Although vasopressin still causes significant dif-
ferences in cardiac output and left ventricular end-systolic
pressure, this difference is significantly less than that before
the addition of 8-bromo-cGMP.
Influence of 8-bromo-cGMP on dose-response curves
of vasopressin. Even more striking is the change in the
dose-response relation between intraatrial vasopressin and
coronary flow (Fig. 5) . The curve for 8-bromo-cGMP is
significantly shifted to the right and EDso is 0.05 U before
addition of 8-bromo-cGMP and 0.12 U in the presence of
8-bromo-cGMP. The relation of vasopressin to total coro-
nary vascular resistance follows a similar pattern (EDsu 0.15
versus 0 .2 U) (Fig . 6) . This inhibition occurs in a noncom-
petitive manner. The presence of 8-bromo-cGMP in the
perfusate also prevents the decrease in cardiac function,
oxygen consumption and development of myocardial aci-
dosis. Apparently, 8-bromo-cGMP is able to overcome the
myocardial effects of intense vasocon striction induced by
vasopressin .
Conclusions. Our results regardin g coronary arter ies
perfusing an intact supported heart preparation suggest that
8-bromo-cGMP can be useful in counteracting coronary ar-
tery constriction in vivo, particularly when the coronary
endothelium has been damaged. We have alread y shown
that the technique described in this report for determination
of resistance in large coronary arteries (color arteriography)
is applicable to the open chest animal and may lend itself
to an investigation of the effect of 8-bromo-cGMP on sub-
epicardial coronary arteries of other large animal s and hu-
mans .
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